A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients

Journal of Cancer - Australia
doi 10.7150/jca.2.329
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Ivyspring International Publisher

Related search

Active Immunotherapy in Malignant Melanoma.

BMJ
1978English

Correlation Between Tumor Regression and T Cell Responses in Melanoma Patients Vaccinated With a MAGE Antigen

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2004English

Functional Analysis of Tumor-Specific Th Cell Responses Detected in Melanoma Patients After Dendritic Cell-Based Immunotherapy

Journal of Immunology
AllergyImmunology
2004English

MAGE-A3 With Cell-Penetrating Domain as an Efficient Therapeutic Cancer Vaccine

JAMA Surgery
Surgery
2014English

Clinical Responses in Patients With Advanced Colorectal Cancer to a Dendritic Cell Based Vaccine

Oncology Reports
MedicineCancer ResearchOncology
1994English

Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy

Journal of Immunology Research
MedicineAllergyImmunology
2018English

Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2015English

188. Hematopoietic Stem Cell Immunotherapy for Melanoma

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2012English

Preclinical Evaluation of a MAGE-A3 Vaccination Utilizing the Oncolytic Maraba Virus Currently in First-In-Human Trials

OncoImmunology
OncologyAllergyImmunology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy